Skip to main content
Premium Trial:

Request an Annual Quote

Publicly Traded RNAi Drug Firms

Premium

With Rosetta Genomics prepping for an initial public offering during this year or next, it is set to join a handful of other companies in the RNAi drugs game that are traded on public markets. To date Alnylam Pharmaceuticals is the only firm to have floated its shares as an RNAi company; all the others were already public when they reorganized to focus on the gene-silencing technology.

Below is a breakdown of the public companies in the space.

Publicly Traded RNAi Drug Firms
Company
Ticker Symbol
Date Founded
Date of IPO/Date Began Trading as RNAi Firm
Stock Price at IPO/Stock Price after Becoming RNAi Firm
Current Stock Price (as of Jan. 26)
Alnylam Pharmaceuticals ALNY July 2002 May 2004
$6.00
$13.80
Benitec BLT.AX February 1997 as Queensland Opal, an opal mining concern. Reorganized into RNAi firm in July 2002. Shares began trading on Australian Stock Exchange under Benitec name in July 2002.
Aus$0.35
Aus$0.18
CytRx CYTR February 1985. Began researching RNAi in April 2003 after corporate reorganization. Began trading as RNAi company in April 2003.
$1.49
$1.19
Genesis Research and Development GEN.AX September 2000. Shifted focus onto RNAi therapeutics around December 2003. Began trading on Australian Stock Exchange with new RNAi focus around December 2003.
Aus$1.00
Aus$0.25
Sirna Therapeutics RNAI January 1992. Changed name to Sirna Therapeutics from Ribozyme Pharmaceuticals, and shifted focus onto RNAi in April 2003. Began trading as Sirna Therapeutics in April 2003.
$4.22
$4.13
SR Pharma SPA.L November 1994. Began researching RNAi therapeutics after July 2005 acquisition of Atugen. Began trading on the London Stock Exchange with an RNAi focus in July 2005.
29.5p
20.5p
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.